StreetInsider.com News Articles

Form 4 Cogent Biosciences, Inc. For: Oct 01 Filed by: Ferrante Karen Jean

Mon, 05 Oct 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20261005/27149208.html

H.C. Wainwright Reiterates Buy Rating on Cogent (COGT)

Wed, 16 Sep 2026 06:55:48 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $55.00 price target on Cogent (NASDAQ: COGT).

The analyst commented: "Earlier today, Cogent announced that the FDA has accepted its NDA for bezuclastinib in advanced systemic mastocytosis (AdvSM), and has set a PDUFA date of June 29th 2027. This NDA submission is supported by results from the Phase 2 APEX trial that was presented at EHA earlier this year. Recall, per the EHA oral presentation, bezuclastinib (n=81; 35% prior TKI) generated a high response rate (54% ORR [24% CR + CRh] per mIWG-MRT-ECNM criteria), with consistent efficacy across AdvSM subtyped, and

FDA accepts Cogent Biosciences NDA for bezuclastinib in AdvSM

Tue, 15 Sep 2026 08:01:25 -0400

Cogent Biosciences, Inc. (Nasdaq: COGT) announced that the U.S. Food and Drug Administration has accepted its New Drug Application for bezuclastinib in patients with Advanced Systemic Mastocytosis, with a PDUFA target action date of June 29, 2027.

The FDA indicated it does not plan to hold an advisory committee meeting and has not identified any potential review issues at this time.

The NDA is supported by data from the APEX pivotal trial, most recently presented at the 2026 European Hematology Association Congress. As of a March 31, 2026 data cutoff, bezuclastinib met its primary endpoint with a 65% overall response rate per

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Tue, 15 Sep 2026 08:00:00 -0400

NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM

PDUFA target action date set for June 29, 2027

WALTHAM, Mass. and BOULDER, Colo., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for bezuclastinib in patients with Advanced Systemic Mastocytosis (AdvSM) and assigned a Prescription Drug User

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Tue, 15 Sep 2026 08:00:00 -0400

NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM

PDUFA target action date set for June 29, 2027

Form 144 Cogent Biosciences, Inc. Filed by: Morris Arlene

Thu, 27 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260827/26990156.html

Form 144 Cogent Biosciences, Inc. Filed by: Morris Arlene

Thu, 27 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260827/26990156.html

H.C. Wainwright Reiterates Buy Rating on Cogent (COGT)

Thu, 20 Aug 2026 06:53:37 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $55.00 price target on Cogent (NASDAQ: COGT).

The analyst commented: "Financial results reported—raising price target. For 2Q26, Cogent recorded a net loss of $0.56 vs. our previously forecasted net loss of $0.55 per share. R&D and SG&A expenses were $70.8M and $31.8M, respectively, vs. our estimates of $72.5M and $28.4M. We now project a full-year 2026 net loss of $2.37 per share compared to our prior estimate of $2.21 per share. Cogent ended 2Q26 with $865.9M in cash and equivalents, which should provide an operational runway into late 2028. We note,

Cogent (COGT) PT Raised to $55 at Piper Sandler

Mon, 17 Aug 2026 07:43:38 -0400

Piper Sandler analyst Allison M. Bratzel raised the price target on Cogent (NASDAQ: COGT) to $55.00 (from $52.00) while maintaining a Overweight rating.

Form SCHEDULE 13G/A Cogent Biosciences, Inc. Filed by: Flynn James E

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921099.html

Form SCHEDULE 13G/A Cogent Biosciences, Inc. Filed by: Flynn James E

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921099.html

Cogent (COGT) PT Raised to $52 at Guggenheim

Wed, 12 Aug 2026 06:56:15 -0400

(Updated - August 12, 2026 6:56 AM EDT)

Guggenheim analyst Charles Zhu raised the price target on Cogent (NASDAQ: COGT) to $52.00 (from $45.00) while maintaining a Buy rating.

The analyst commented: "COGT reported 2Q26 earnings and remains on track for two near term FDA decisions on bezuclastinib (KIT inhibitor): 2L GIST (in combination with sunitinib) with a PDUFA date of November 30, 2026, and NonAdvSM with a PDUFA date of December 30, 2026. The AdvSM NDA was submitted on June 30 following positive full APEX data at EHA (here), which showed a competitive efficacy profile vs. Ayvakit alongside a differentiated safety

Cogent (COGT) PT Raised to $52 at Guggenheim

Wed, 12 Aug 2026 06:56:15 -0400

(Updated - August 12, 2026 6:56 AM EDT)

Guggenheim analyst Charles Zhu raised the price target on Cogent (NASDAQ: COGT) to $52.00 (from $45.00) while maintaining a Buy rating.

Form 8-K Cogent Biosciences, Inc. For: Aug 10

Mon, 10 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260810/26899200.html

Form 8-K Cogent Biosciences, Inc. For: Aug 10

Mon, 10 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260810/26899200.html

Form 424B5 Cogent Biosciences, Inc.

Mon, 10 Aug 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20260810/26899181.html

Form 424B5 Cogent Biosciences, Inc.

Mon, 10 Aug 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20260810/26899181.html

Form 10-Q Cogent Biosciences, Inc. For: Jun 30

Mon, 10 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260810/26898005.html

Form 10-Q Cogent Biosciences, Inc. For: Jun 30

Mon, 10 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260810/26898005.html

Form 8-K Cogent Biosciences, Inc. For: Aug 10

Mon, 10 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260810/26894813.html

Form 8-K Cogent Biosciences, Inc. For: Aug 10

Mon, 10 Aug 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260810/26894813.html

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Mon, 10 Aug 2026 08:00:00 -0400

On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitted to FDA on June 30

Completed onboarding of expert cross-functional Cogent customer-facing team, including all field-based commercial and medical team members

Strong pro forma cash balance of $865.9 million, sufficient to fund operations into late 2028

WALTHAM, Mass. and BOULDER, Colo., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Mon, 10 Aug 2026 08:00:00 -0400

Completed onboarding of expert cross-functional Cogent customer-facing team, including all field-based commercial and medical team members

Strong pro forma cash balance of $865.9 million, sufficient to fund operations into late 2028

WALTHAM, Mass. and BOULDER, Colo., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Mon, 10 Aug 2026 08:00:00 -0400

Completed onboarding of expert cross-functional Cogent customer-facing team, including all field-based commercial and medical team members

Strong pro forma cash balance of $865.9 million, sufficient to fund operations into late 2028

WALTHAM, Mass. and BOULDER, Colo., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

Mon, 10 Aug 2026 08:00:00 -0400

Completed onboarding of expert cross-functional Cogent customer-facing team, including all field-based commercial and medical team members

Strong pro forma cash balance of $865.9 million, sufficient to fund operations into late 2028

WALTHAM, Mass. and BOULDER, Colo., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically